Endosense has obtained CE mark approval for its TactiCath Quartz force-sensing ablation catheter for the treatment of atrial fibrillation and supraventricular tachycardia.

The TactiCath Quartz includes a new force sensor that provides stability and avoids the need for pre-procedure calibration, while the lesion index parameter provides an improved, real-time indication of lesion quality during catheter ablation procedures.

The ablation catheter also incorporates a user friendly graphical interface, and signal processing and digital output that facilitates connectivity with imaging devices and other equipment in the lab.

In cooperation with the company’s distributor Biotronik, the first cases using the new device have been performed by Dipen Shah from University Hospital of Geneva, Georg Nolker from Heart and Diabetes Center as well as Reza Wakili and Heidi Estner from University Hospital Grosshadern in Munich, Germany.

Endosense president and chief executive officer Jan Keltjens said the company believes that the third generation TactiCath device will enhance ease of use and performance, and will further advance the trend towards force-sensing becoming part of the standard of care.